










<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/css" href="http://52.214.119.220/wiki/skins/common/feed.css?97"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>4j23 - Revision history</title>
		<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;action=history</link>
		<description>Revision history for this page on the wiki</description>
		<language>en</language>
		<generator>MediaWiki 1.11.2</generator>
		<lastBuildDate>Wed, 15 Apr 2026 12:58:38 GMT</lastBuildDate>
		<item>
			<title>OCA at 15:35, 20 September 2023</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=3875627&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 15:35, 20 September 2023&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 4:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 4:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [https://proteopedia.org/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [https://proteopedia.org/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[https://proteopedia.org/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [https://pdbe.org/4j23 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [https://www.ebi.ac.uk/pdbsum/4j23 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4j23 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='method'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Empirical_models|Method:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&amp;quot;methodDat&amp;quot;&amp;gt;X-ray diffraction, [[Resolution|Resolution]] 3.882&amp;amp;#8491;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[https://proteopedia.org/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [https://pdbe.org/4j23 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [https://www.ebi.ac.uk/pdbsum/4j23 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4j23 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 20 Sep 2023 15:35:08 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 21:25, 16 November 2022</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=3667014&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 21:25, 16 November 2022&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right'caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right'caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://en.wikipedia.org/wiki/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human Human&lt;/del&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://en.wikipedia.org/wiki/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo_sapiens Homo sapiens&lt;/ins&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN]), FGF1, FGFA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://pdbe.org/4j23 PDBe], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.ebi.ac.uk/pdbsum/4j23 PDBsum], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=4j23 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://pdbe.org/4j23 PDBe], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.ebi.ac.uk/pdbsum/4j23 PDBsum], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=4j23 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123500 123500&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123150 123150&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101200 101200&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101600 101600&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123790 123790&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/609579 609579&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/149730 149730&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/207410 207410&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/614592 614592&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123500 123500]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123150 123150]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101200 101200]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101600 101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123790 123790]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/609579 609579]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/149730 149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/207410 207410]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/614592 614592]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; [[http://www.uniprot.org/uniprot/FGF1_HUMAN FGF1_HUMAN]] Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.&amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:20145243&amp;lt;/ref&amp;gt;  &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 29:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 27:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo sapiens&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;M]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kudlinzki D]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kudlinzki&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;D]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Saxena K]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Saxena&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;K]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schieborr U]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schieborr&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;U]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schreuder H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schreuder&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schwalbe H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schwalbe&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Sreeramulu S]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Sreeramulu&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;S&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Fgf binding]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Immunoglobulin c-2 type]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Membrane protein]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Protein binding]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Protein-protein complex]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor domain]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Signaling protein]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Signaling protein-transferase complex]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Transferase&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 16 Nov 2022 21:25:38 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 12:01, 17 July 2019</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=3069759&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 12:01, 17 July 2019&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right' caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right'caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 23:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 23:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor|Fibroblast growth factor]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;3D structures&lt;/ins&gt;|Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;3D structures&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;receptor 3D &lt;/ins&gt;receptor|Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;receptor 3D &lt;/ins&gt;receptor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Human]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Human]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer, M]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer, M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 17 Jul 2019 12:01:22 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 11:02, 11 August 2016</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=2659984&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 11:02, 11 August 2016&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right' caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j23' size='340' side='right' caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 5:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 6:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN]), FGF1, FGFA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN]), FGF1, FGFA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [http://www.ebi.ac.uk/pdbsum/4j23 PDBsum]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;], [http://pdbe.org/4j23 PDBe&lt;/ins&gt;], [http://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [http://www.ebi.ac.uk/pdbsum/4j23 PDBsum&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j23 ProSAT&lt;/ins&gt;]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 19:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 20:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, a database of the U.S. National Library of Medicine.&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, a database of the U.S. National Library of Medicine.&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 4j23&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor|Fibroblast growth factor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Thu, 11 Aug 2016 11:02:17 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 08:21, 25 January 2015</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=2366060&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 08:21, 25 January 2015&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{STRUCTURE_4j23|  PDB=4j23  |  SCENE=  }} &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;=&lt;/del&gt;==Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex===&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;StructureSection load&lt;/ins&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'4j23' size='340' side='right' caption='[[4j23]], [[Resolution|resolution]] 3.88&amp;amp;Aring;' scene=''&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{ABSTRACT_PUBMED_23597563}}&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Structural highlights ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j23]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J23 FirstGlance]. &amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Disease==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN]), FGF1, FGFA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j23 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4j23 RCSB], [http://www.ebi.ac.uk/pdbsum/4j23 PDBsum]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/table&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/entry/614592 614592]]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/entry/614592 614592]]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  [[http://www.uniprot.org/uniprot/FGF1_HUMAN FGF1_HUMAN]] Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.&amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:20145243&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling network plays an important role in cell growth, survival, differentiation, and angiogenesis. Deregulation of FGFR signaling can lead to cancer development. Here, we report an FGFR inhibitor, SSR128129E (SSR), that binds to the extracellular part of the receptor. SSR does not compete with FGF for binding to FGFR but inhibits FGF-induced signaling linked to FGFR internalization in an allosteric manner, as shown by crystallography studies, nuclear magnetic resonance, Fourier transform infrared spectroscopy, molecular dynamics simulations, free energy calculations, structure-activity relationship analysis, and FGFR mutagenesis. Overall, SSR is a small molecule allosteric inhibitor of FGF/FGFR signaling, acting via binding to the extracellular part of the FGFR.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Function==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Molecular mechanism &lt;/ins&gt;of &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SSR128129E&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;an extracellularly acting&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;small-molecule&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;allosteric inhibitor &lt;/ins&gt;of &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;FGF receptor signaling&lt;/ins&gt;.,&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Herbert C&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Schieborr U&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Saxena K&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Juraszek J&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;De Smet F&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Alcouffe C&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Bianciotto M&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Saladino G&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Sibrac D&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Kudlinzki D&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Sreeramulu S&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Brown A&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Rigon P&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Herault JP&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Lassalle G&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Blundell TL&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Rousseau F, Gils A, Schymkowitz J, Tompa P, Herbert JM&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Carmeliet P, Gervasio FL, Schwalbe H, Bono F Cancer Cell&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2013 Apr 15;23(4):489&lt;/ins&gt;-&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;501&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;doi&lt;/ins&gt;: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;10.1016&lt;/ins&gt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;j&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ccr&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2013&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;02.018&lt;/ins&gt;. PMID:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;23597563&lt;/ins&gt;&amp;lt;ref&amp;gt;PMID:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;23597563&lt;/ins&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation &lt;/del&gt;of &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;cell proliferation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;differentiation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;migration and apoptosis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and in the regulation &lt;/del&gt;of &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;embryonic development&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Required for normal embryonic patterning&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;trophoblast function&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;limb bud development&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;lung morphogenesis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proliferation and apoptosis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1&lt;/del&gt;,&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;4&lt;/del&gt;,&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;GAB1&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;PIK3R1 and SOS1&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and mediates activation of RAS&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;MAPK1/ERK2&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;MAPK3/ERK1 and the MAP kinase signaling pathway&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;internalization and degradation lead to aberrant signaling&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Over&lt;/del&gt;-&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;expressed FGFR2 promotes activation of STAT1&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;PMID&lt;/del&gt;:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  [[http:/&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;www&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;uniprot&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org/uniprot/FGF1_HUMAN FGF1_HUMAN]] Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Functions as potent mitogen in vitro&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&lt;/del&gt;PMID:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &lt;/del&gt;&amp;lt;ref&amp;gt;PMID:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;20145243&lt;/del&gt;&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==About this Structure==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, &lt;/ins&gt;a &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;database of the U&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;S&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;National Library of Medicine&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[4j23]] is &lt;/del&gt;a &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2 chain structure&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Full crystallographic information is available from [http://oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ac.il&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca-bin/ocashort?id=4J23 OCA]. &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;&lt;/ins&gt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;div&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Reference&lt;/del&gt;==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;See Also&lt;/ins&gt;==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref group&lt;/del&gt;=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot;xtra&amp;quot;&amp;gt;PMID:023597563&amp;lt;/ref&amp;gt;&lt;/del&gt;&amp;lt;references &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;group=&amp;quot;xtra&amp;quot;&lt;/del&gt;/&amp;gt;&amp;lt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;references&lt;/del&gt;/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;= References ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;__TOC__&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;StructureSection&lt;/ins&gt;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Human]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer, M&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Dreyer, M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kudlinzki, D&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kudlinzki, D]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Saxena, K&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Saxena, K]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schieborr, U&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schieborr, U]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schreuder, H&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schreuder, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schwalbe, H&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Schwalbe, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Sreeramulu, S&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Sreeramulu, S]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Fgf binding]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Fgf binding]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Immunoglobulin c-2 type]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Immunoglobulin c-2 type]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Sun, 25 Jan 2015 08:21:00 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 15:48, 3 March 2014</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=1899705&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 15:48, 3 March 2014&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;{{STRUCTURE_4j23|  PDB=4j23  |  SCENE=  }} &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;{{STRUCTURE_4j23|  PDB=4j23  |  SCENE=  }} &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;===Low resolution crystal structure of the FGFR2D2D3/FGF1/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SSR128545 &lt;/del&gt;complex===&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;===Low resolution crystal structure of the FGFR2D2D3/FGF1/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SR128545 &lt;/ins&gt;complex===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;{{ABSTRACT_PUBMED_23597563}}&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;{{ABSTRACT_PUBMED_23597563}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Mon, 03 Mar 2014 15:48:12 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 17:32, 19 February 2014</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=1898593&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 17:32, 19 February 2014&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'''Unreleased &lt;/del&gt;structure&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{STRUCTURE_4j23|  PDB=4j23  |  SCENE=  }} &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;===Low resolution crystal &lt;/ins&gt;structure &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;of the FGFR2D2D3/FGF1/SSR128545 complex===&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{ABSTRACT_PUBMED_23597563}}&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;4j23 &lt;/del&gt;is &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ON HOLD &lt;/del&gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;until Mar 06 2015&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Disease==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. &lt;/ins&gt;The &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/&lt;/ins&gt;entry&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;/614592 614592]]. BBDS &lt;/ins&gt;is &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;/ins&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Authors&lt;/del&gt;: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Kudlinzki&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;D&lt;/del&gt;., &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Schwalbe&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;H&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Function==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http&lt;/ins&gt;:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;//www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;differentiation, migration and apoptosis, and in the regulation of embryonic development&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Required for normal embryonic patterning&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;trophoblast function&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;limb bud development, lung morphogenesis, osteogenesis and skin development&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  [[http://www.uniprot.org/uniprot/FGF1_HUMAN FGF1_HUMAN]] Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.&amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:20145243&amp;lt;/ref&amp;gt;  &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Description&lt;/del&gt;: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Low resolution polyA backbone model of the FGFR2D2D3&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;FGF1&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SSR128545 &lt;/del&gt;complex&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==About this Structure==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[4j23]] is a 2 chain structure. Full crystallographic information is available from [http&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca.weizmann.ac.il/oca-bin/ocashort?id=4J23 OCA]. &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Reference==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:023597563&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Dreyer, M.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Kudlinzki, D.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Saxena, K.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Schieborr, U.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Schreuder, H.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Schwalbe, H.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Sreeramulu, S.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Fgf binding]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Immunoglobulin c-2 type]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Membrane protein]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Protein binding]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Protein-protein &lt;/ins&gt;complex&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor domain]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Signaling protein]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Signaling protein-transferase complex]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Transferase]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 19 Feb 2014 17:32:49 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 04:45, 13 February 2014</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=1895992&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 04:45, 13 February 2014&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD  until &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Feb &lt;/del&gt;06 2015&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD  until &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Mar &lt;/ins&gt;06 2015&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Thu, 13 Feb 2014 04:45:11 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 09:54, 5 February 2014</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=1893740&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 09:54, 5 February 2014&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD  until &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;sometime in the future&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD  until &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Feb 06 2015&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 05 Feb 2014 09:54:11 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
		<item>
			<title>OCA at 13:29, 20 February 2013</title>
			<link>http://52.214.119.220/wiki/index.php?title=4j23&amp;diff=1724102&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 13:29, 20 February 2013&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j23 is ON HOLD &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; until sometime in the future&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Kudlinzki, D., Schwalbe, H.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Low resolution polyA backbone model of the FGFR2D2D3/FGF1/SSR128545 complex&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 20 Feb 2013 13:29:01 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:4j23</comments>		</item>
	</channel>
</rss>